0001005201-19-000021.txt : 20190214
0001005201-19-000021.hdr.sgml : 20190214
20190214162006
ACCESSION NUMBER: 0001005201-19-000021
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190212
FILED AS OF DATE: 20190214
DATE AS OF CHANGE: 20190214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Peisert Daniel A.
CENTRAL INDEX KEY: 0001758376
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-13111
FILM NUMBER: 19606669
MAIL ADDRESS:
STREET 1: C/O ASSERTIO THERAPEUTICS, INC.
STREET 2: 100 SOUTH SAUNDERS ROAD, SUITE 300
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Assertio Therapeutics, Inc
CENTRAL INDEX KEY: 0001005201
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943229046
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SOUTH SAUNDERS RD
STREET 2: SUITE 300
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
BUSINESS PHONE: (224) 419-7106
MAIL ADDRESS:
STREET 1: 100 SOUTH SAUNDERS RD
STREET 2: SUITE 300
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
FORMER COMPANY:
FORMER CONFORMED NAME: DEPOMED INC
DATE OF NAME CHANGE: 19970408
4
1
wf-form4_155017919253942.xml
FORM 4
X0306
4
2019-02-12
0
0001005201
Assertio Therapeutics, Inc
ASRT
0001758376
Peisert Daniel A.
ASSERTIO THERAPEUTICS, INC.
100 SOUTH SAUNDERS ROAD, SUITE 300
LAKE FOREST
IL
60045
0
1
0
0
SVP and CFO
Restricted Stock Units
2019-02-12
4
A
0
82763
0
A
2022-02-12
Common Stock
82763.0
82763
D
Performance Shares
2019-02-12
4
A
0
4087
0
A
Common Stock
4087.0
4087
D
Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock.
One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022, assuming continued employment through the applicable vesting date.
The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
Represents the current tranche of performance shares earned under the 2018 performance share award as of February 12, 2019, at which date the Compensation Committee certified the extent to which the current tranche performance criteria were met. Each earned performance share represents the contingent right to receive one share of common stock.
Each performance share will convert into one share of common stock upon vesting and settlement in the first quarter of 2021.
/s/ Erin R. McQuade, attorney in fact
2019-02-14